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Abstract
We present a mixture-of-experts approach for HIV therapy selection. The heterogeneity in patient data makes it difficult
for one particular model to succeed at providing suitable therapy predictions for all patients. An appropriate means
for addressing this heterogeneity is through combining kernel and model-based techniques. These methods capture
different kinds of information: kernel-based methods are able to identify clusters of similar patients, and work well
when modelling the viral response for these groups. In contrast, model-based methods capture the sequential process
of decision making, and are able to find simpler, yet accurate patterns in response for patients outside these groups.
We take advantage of this information by proposing a mixture-of-experts model that automatically selects between
the methods in order to assign the most appropriate therapy choice to an individual. Overall, we verify that therapy
combinations proposed using this approach significantly outperform previous methods.
Introduction
Human Immunodeficiency virus (HIV-1) affects over 36 million people worldwide [1]. To date, the only practical
treatment for HIV is life-long administration of combinations of antiretroviral drugs targeting different phases of viral
replication. However, repeated use of the same combinations of drugs encourages the formation of drug-resistant viral
strains. These drug-resistant viral strains are stored and render the future administration of the same or similar therapy
combinations ineffective. The large number of potential therapy combinations and the high mutation rate of the virus
make searching for an effective therapy particularly challenging, especially for patients at advanced stages of infection.
Several computational approaches have been developed to address this challenge. Regression-based approaches map
elements of a patient’s history directly to some output, such as virological response. For example, Altmann et al. [2]
use tree-based learning to predict a patient’s virological response using evolutionary information, while others [3, 4]
predict virological response based on the patient’s treatment history. Treatment recommendations can then be made
based on what therapy combination is expected to have the best response. More recently, Bogojeska et al. [5] present a
kernel-based approach that predicts whether a particular therapy choice will be successful given information about a
patient and their treatment history—where success is defined by the viral load dropping below 400 copies/mL after at
least 21 days of treatment under the therapy. The premise here is that patients with similar treatment histories are likely
to respond to treatment in a similar way.
Unfortunately, none of these regression-based approaches directly address the sequential nature of the therapy selection
process: that a choice of combination now might result in drug-resistant viral strains that may be hard to control later.
Approaches based on reinforcement learning [6] make this sequential nature explicit: they output a treatment policy
that selects therapy combinations not only to optimise virological response in the present, but also in the future. While
reinforcement learning has been used to optimise HIV treatment strategies in simulation studies [7, 8], reasoning about
possible futures from limited observational data can make these approaches brittle in practice.
In this work, we present a mixture-of-experts approach [9] that combines the strengths of both kernel-based regression
and reinforcement-learning approaches for therapy selection in HIV. Kernel-based regression approaches excel when
there are clusters of similar patients; they can model the idiosyncrasies in viral response specific to those patients.
However, their prediction quality drops for patients that are not part of a tight cluster. In contrast, model-based
reinforcement learning approaches first build a model of how the patient is expected to respond and then use that
model to reason about how well a series of therapy selections will perform. These approaches tend to find simpler but
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more robust patterns of response, a better alternative for patients outside of clusters. Our mixture-of-experts approach
automatically chooses between these two options.
Specifically, our work makes the following contributions:
• We modify the kernel-based approach [5] to predict not just whether a therapy combination will be immediately
successful, but whether it will control HIV in the long term. We demonstrate that optimising for immediate viral
load reduction does not control viral loads or mutations in the long term.
• We train a model-based learner and combine it with the kernel-based approach via mixture-of-experts. On a
hold-out set of 3 000 patients, we demonstrate that the therapy combinations proposed by our treatment policy
outperform previous approaches.
Our post-hoc investigation also support our hypothesis that the kernel-based approach is used when a patient lies as part
of a cluster, whereas the model-based approach is used for patients that have no nearby neighbours; this observation
suggests that more nuanced approaches are needed to make optimal treatment recommendations for patients with HIV.
Background & Related Work
Kernel-based history-alignment models for HIV therapy prediction It is well-established that a patient’s prior
history is a key factor for predicting the efficacy of HIV treatment [3, 4]. Bogojeska et al. [5] use this fact in a history
alignment model that measures the similarity between two therapy sequences1. Two therapy sequences are considered
to be similar if they consist of similar drug combinations, are administered in a similar order, and produce similar
genomic fingerprints in the viral population. If two patients have similar histories, Bogojeska et al. [5] demonstrate that
they often respond similarly to treatment. Specifically, the history-alignment model first uses a resistance mutations
kernel to quantify the pairwise similarities between different therapy combinations. Resistance mutations are the Single
Nucleotide Polymorphisms (SNPs) in the HIV viral genome identified by the International AIDS Society as being
associated with drug resistance [10]. The kernel assumes that similarity between the different drug groups is additive,
which is a reasonable assumption since drugs belonging to different groups have different therapeutic targets and/or
modes of action, and thus can be assumed to act independently.
Formally, the resistance mutations kernel is defined as follows. Let G denote the set of different drug groups.
In our clinical data set we have five different drug groups: Nucleoside Reverse Transcriptase Inhibitors (NRTIs),
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Integrase Inhibitors (IIs) and
Entry Inhibitors (EIs). Let uzg and uz′g be the sets of resistance-relevant mutations for the drugs occurring in drug
group g ∈ G of the therapies z and z′, respectively. The pairwise similarity between the drug-g mutations of the drug
combinations z and z′ is then calculated using the Jaccard index:
simg(z, z′) =
|uzg
⋂
uz′g|
|uzg
⋃
uz′g| , (1)
where | · | denotes set cardinality. We then derive the similarity km(z, z′) between the therapies z and z′ by averaging
the similarities of their corresponding drug groups:
km(z, z′) =
∑
g∈G
simg(z, z′)
|G| . (2)
Since the group similarities simg(z, z′) lie in the interval [0, 1], the values of the resistance mutations kernel are
also within [0, 1]. Intuitively, the higher the number of common resistance-relevant mutations associated with the
corresponding sets of drugs making up the two therapies of interest, the higher their similarity. In this way the resistance
mutations kernel also accounts for the similarity of the genetic fingerprint of the potential latent virus populations of
the compared therapies. Furthermore, this kernel represents drugs in terms of their mutation profile and, by doing so,
1The combinations of drugs a patient takes at a particular time is defined as a therapy. A therapy sequence refers to a sequence of such combinations
over time.
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allows for high group similarity for non-identical drugs that have very similar resistance mutation profiles and thus
takes the high level of cross resistance within the same drug class into account.
The therapy sequence alignment kernel uses the resistance mutations kernel and in what follows, we describe it in
detail. Let start(t) denote the point of time when the therapy t was started and patient(t) denote the patient identifier
corresponding to therapy sample t. Then:
ρ(t) = {z | (start(z) ≤ start(t)) and (patient(z) = patient(t))} (3)
denotes the complete treatment record associated with the therapy sample t and is referred to as therapy sequence. It
contains all known therapies administered to patient(t) not later than start(t) ordered by their corresponding starting
times, from older to newer. Note that each therapy sequence also contains the current therapy, the most recent therapy
in the therapy sequence ρ(t) is t. The main objective is to quantify the similarity of therapy sequences by considering
two therapy sequences as similar if they consist of similar drug combinations administered in a similar order and
producing similar genomic fingerprints in the latent viral population. For this purpose, first the pairwise similarity
between different drug combinations is quantified using the resistance mutations kernel and then the overall similarity
between two therapy sequences of interest is computed using the kernel and the information on the order in which the
therapies were administered. As the treatment history similarity score needs to reflect both the similarity of the different
therapies comprising the therapy sequences and the order in which they were administered, it is computed by adapting
the the Needleman-Wunsch score commonly used for assessing the quality of an alignment of a protein or nucleic acid
sequences [11]. The alphabet used for the therapy sequence alignment consists of all distinct drug combinations making
up the clinical data set. The resistance mutations kernel in Equation 2 determines the pairwise similarities s between its
letters (therapies). As each therapy sequence ends with the current (most recent) therapy - the one that determines the
label of the sample, the sequence alignment is adapted such that the rightmost (most recent) therapies (alphabet letters)
are always matched, i.e. no gaps are allowed at the right end of an alignment.
The score from the alignment kernel, together with the viral genotype and drug history information, can then be used to
train a regression model for predicting the outcome of a therapy in terms of success or failure. A therapy is defined as
successful if that patient’s viral load falls below 400 copies/mL after 21 days of treatment under the therapy [5]. In our
work, we will replace this success criteria with the potential long-term value of a therapy choice.
BayesianModel-Based Reinforcement Learning. Many problems, including HIV therapy selection, involve making
a sequence of decisions with long-term consequences. The reinforcement learning framework formalises the sequential
decision-making process as a series of repeated exchanges between an agent and its environment. At each time step, the
agent selects an action a (such as a drug combination) and the environment returns some observations o (e.g. CD4
counts, viral loads, mutations) as well as an immediate reward r (e.g. did the viral load drop below a desired threshold).
Given a history of length t, h = {a1, o1, r1 . . . , at, ot, rt}, the agent’s goal is to choose the subsequent action such
that it maximises discounted sum of its expected rewards, E[
∑
t γtrt], where γ ∈ [0, 1) trades off between current and
future rewards.
This decision-making task may be formulated as a Partially Observable Markov Decision Process (POMDP) [12].
A POMDP m is defined by a finite set of hidden states S (e.g. a patient’s true physiological state), actions A and
observations O. A transition function T (s′|s, a) specifies the probability of transitioning from state s to s′ when taking
an action a. Similarly, an observation function Ω(o|s, a) specifies the probability of observing o from state s when
taking action a. The reward function R : S × A → R specifies the immediate reward that an agent receives upon
performing an action from a particular state.
When the agent has full knowledge of its environment, the current state st describes everything about the past that is
necessary to predict the future. However, in a POMDP the state is never directly observed. Instead, an agent perceives
an observation at each time step. This observation, unlike the state, does not capture all the information from the past
that may be necessary to make future decisions [13]. In particular, the entire history ht may still be necessary to make
predictions about the future. To overcome this problem, upon perceiving an observation at each time step, the agent
must maintain a belief state b ∈ ∆S that specifies the probability of being in each state given the series of actions
performed and observations received thus far, from some initial belief b0. The belief state may be updated at each time
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step according to Bayes’ rule [14] :
bt+1(s) = Ω(o|s, a)
∑
s′∈S
T (s′|s, a)bt(s′)
Pr(o|b, a) , (4)
where Pr(o|b, a) = Ω(o|s, a)∑s∈S T (s′|s, a)bt(s). Optimal decisions are subsequently made on the basis of these
beliefs.
The Bayesian reinforcement learning framework involves two steps. First, the agent learns a distribution over possible
models p(m) based on data—that is, we must first infer patterns of response based on the treatment histories that we
have. Next, we must use these models to determine what would be the most optimal set of treatment decisions, known
as a treatment policy. Reasoning about outcomes given a distribution over models ensures that we account for the
uncertainty of not knowing a patient’s true physiological dynamics. We summarise the core ideas for each of these
steps below; for more details we refer the reader to [13, 14, 15].
If we choose to model the patient’s hidden physiological state as a discrete variable, then we can model the uncertainty
over the transitions T (s′|s, a) and observations Ω(o|s, a) with Dirichlet distributions. Sampling a model given this
Dirichlet prior is relatively straightforward; we only need to keep track of the number of times we believe a physiological
state may have been visited [15]:
T (s′|s, a) = φ
a
s,s′∑
s′′∈S φ
a
s,s′′
Ω(o|s, a) = ψ
a
s,o∑
o′∈Ω φ
a
s,o′
. (5)
where φas,s′∀s′ and ψas′,o∀o monitor the statistics of how often particular transitions and observations were observed.
We sample a set of such models here. Given a set of models, we can find a (near) optimal treatment policy via forward
search over the beliefs [15]. This process involves simulating a forward-looking tree of possible outcomes of a particular
treatment policy, and using this to search for the actions that optimise these outcomes.
Methods
We now propose our mixture-of-experts approach for HIV therapy selection. First, we provide the specifics of the
data we have used for experimentation. Next, we explain the structure of our mixture-of-experts model in its specific
components. For our first expert, we modify the history alignment model of [5] to predict whether a drug combination
will optimise long-term outcomes rather than immediate outcomes. Our second expert is a Bayesian POMDP. In our
results, we will demonstrate that combining the Bayesian POMDP and history alignment kernel in our mixture-of-experts
approach succeeds at delivering the most appropriate therapy choice for an individual that is tailored to their specific
situation.
Cohorts The data used for this research comes from the EuResist database [16]. The entire EuResist database is
among the largest available HIV data sources with records of HIV genotypes and response to antiretroviral therapy for
more than 65 000 patients. We focus on a subset of this data set, where we make use of the genotypic and treatment
response data of 32 960 patients, together with their corresponding CD4+ and viral load measurements, gender, age, risk
group, and number of past treatments recorded. The data set is a heterogenous set with patients of various ethnicities
coming from over 100 countries, ranging from heavily pre-treated to having short treatment histories. In the modelling
below, we limit ourselves to the 312 most common drug combinations that occur in the cohort. These drug combinations
span 20 total drugs. The database has previously been used to build models such as the therapy alignment model, to
predict the outcome of a particular therapy [17, 18]. We are however, specifically interested in optimising the therapy
choice for a patient.
Mixture-of-experts architecture for choosing between models. We present a mixture-of-experts approach for HIV
therapy selection. The idea is primarily based on the ‘divide and conquer’ principle, where a complex problem is solved
by dividing it into simpler problems whose solutions can then be combined to provide a reasonable overall solution.
The mixture-of-experts [9] is a technique that allows us to overcome the problems associated with choosing a particular
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model, by automatically assigning regions of the input space to different models. In this way, if two models exhibit
complementary properties and operate well in different regions of the input space, we can take advantage of both. In our
case, we hypothesise that kernel-based methods do best for patients that are part of a cluster—that is, when there are
many similar patients to draw inference from. However, they can perform poorly for patients that are farther from any
cluster because they are not particularly similar to any other patient in the cohort. In contrast, the model-based POMDP
approach tends to over-simplify: clearly, patients cannot be fully modelled as having discrete physiological states.
However, an over-simplified model of HIV response may be preferable to the completely inaccurate prediction that we
may make if we map a patient to dissimilar patient. However, the question remains of how to choose between the two
experts in a formal way. The mixture-of-experts model provides an automatic solution to this problem of choosing
between these methods.
The general architecture for a mixture-of-experts model consists of a set of expert classifiers, followed by a gating
network. The gating network is typically not a classifier, but a combination rule to determine which classifier to select.
In this particular case, we consider the policies produced by both the POMDP and alignment kernel approaches and
would like to select between policies depending on a patient’s particular situation. The model takes as input a set of
viral load measurements, gender, age, risk group, resistance mutations, number of past treatments recorded, the lower
quantile of the distance between a patient and their neighbours, and the length of the treatment history, as well as the
policy parameters from both the POMDP and alignment kernel models. The outputs consist of the learned policies or
therapy combinations under each model. We train classification models using these features to determine which policies
should ultimately be applied for each patient. In principle, any classification model can be used for this purpose (as is
the case in all mixture-of-expert models). We specifically used random forest models here, where hyperparameters such
as the number of trees etc were chosen by experimenting on a separate hold-out set. In this case the number of trees
used is 500. The overall outcome of the mixture-of-experts approach is thus a decision of which treatment policy is
optimal for a patient (in terms of either the POMDP or alignment kernel models).
Long-term Reward Criterion Following [7, 8], we propose the following immediate reward function:
rt =
{
−0.7 log Vt + 0.6 log Tt − 0.2|M |, if Vt is above detection limits
5 + 0.6 log Tt − 0.2|M |, if Vt is below detection limits,
where Vt is the viral load (in copies/mL), Tt is the CD4+ count (in cells/mL), and |M | is the number of mutations at
time t respectively. This function penalise instances where a patient’s viral load increases and rewards instances where
a patient’s CD4+ count increases (more weight is placed on the viral load, as it is an earlier indicator of whether a
therapy is working). We also penalise on the basis of the number of mutations a patient has at a particular time, as these
may ultimately contribute to resistance and therapy failure. There is also a bonus for if the viral load is below detectable
limits as this is something we would like to sustain over time. The long-term reward criterion sums these immediate
rewards over the patient’s history.
A kernel-based approach for HIV therapy selection that optimises long-term rewards. The history alignment
model for predicting therapy outcome presented in the background was trained to predict whether a drug combination
would be immediately successful. In the following, we call the treatment policy that optimises for immediate success
the ‘Short-Term History Alignment’ model. We adapt this model in two ways: first, convert the binary problem of ‘Will
this drug combination succeed?’ into a multi-class problem of ‘Which drug combination should I choose?’ (we consider
the 312 most common drug combinations). Second, and more importantly, this prediction is made by summing over all
the time-steps in the patient’s future history. We call this treatment policy the ‘Long-Term History Alignment’ model.
A Bayesian POMDP for HIV therapy selection The RL framework introduced in Section 2 provides a natural way
of modelling the sequential decision-making process of therapy selection.
As before, we limit our actions to the 312 most common drug combinations in the cohort and learn a model with 7
hidden physiological states. Our observation space consists of (a) binning the values of the viral load using a log scale
of [0.0, 1.0, 10.0, 1000, 10000, 10M, 100M] copies/ML2, (b) the 70 resistance mutations that may occur as a result
2One could have equally well modelled the data as continuous values with a Gaussian emission model.
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of a particular therapy together with a patient’s CD4+ count, gender, risk group. Overall the procedure of interaction
between an agent and its environment is illustrated in Figure 1.
To learn the parameters for the transitions and emissions, one option would be to fix the parameters on the basis of
historical data. However, this approach would assume that the parameters are known with certainty. In reality, these
quantities are highly uncertain, and should thus be learned through the process of monitoring and managing patients.
Hence we treat the parameters in a Bayesian manner (as outlined in the background section), where the agent can
explicitly track its uncertainty and refine its knowledge as a result. We model time in discrete increments of 6 months,
and perform a forward search for therapy choices that optimise outcomes over a 5 year horizon (10 total steps).
Figure 1. HIV Therapy Selection as a POMDP problem.
Evaluation Procedure So far, we have presented several approaches to tackling the HIV therapy selection problem:
the history alignment models, the model-based approaches, and the mixture-of-experts. How can we know which has
better performance, given only retrospective data in which completely different treatment decisions were made? A
series of off-policy evaluation strategies have been proposed to address this question. In our results, we compare our
approaches using three different schemes to show that our results are robust to the choice of off-policy evaluation:
• Importance Sampling [19] corrects the mismatch between the treatment policy to be evaluated and the treatment
decisions made for the cohort using importance sampling. It is unbiased but can have high variance.
• Weighted Importance Sampling [20] attempts to reduce this variance by weighting the importance scores.
• Doubly Robust Evaluation [21] further reduces variance and acheives consistency by coupling the importance
score with a regression estimate of the value of the treatment policy. The procedure works well if importance
ratio between the treatment policy to be evaluated and the actual decisions is balanced or the regression estimate
is accurate.
Results
Table 1 compares the performance of the history alignment method, the POMDP and the mixture-of-experts against
a random policy where a completely random therapy choice is made. The evaluation is performed for a test set of
3 000 randomly selected patients from the cohorts. The performance is measured in terms of the average accumulated
long-term rewards over a period of 5 years with their standard deviations. A higher value indicates a better performing
treatment policy.
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Doubly Robust Importance Sampling Weighted Importance
Random Policy –2.31 +− 1.42 –3.48 +− 1.36 –2.80 +− 1.27
Short-term History Alignment 2.17 +−1.47 2.14 +−1.22 2.15 +−1.16
Long-term History Alignment 9.48 +− 1.90 5.42 +− 1.93 6.74 +− 1.89
POMDP 6.34 +− 2.15 4.36 +− 2.38 6.76 +− 2.24
Mixture-of-experts 11.47 +− 1.38 12.25 +− 1.41 11.23 +− 1.40
Table 1. Off-Policy evaluation using importance sampling, weighted importance sampling and doubly robust methods
for different therapy selection models.
Figure 2. Mixture-of-experts model choice over (a) distances to closest neighbour and, (b) varying history lengths.
Optimising for long-term health produces different treatment policies than predicting the most common next
therapy Table 1 shows that the short-term history alignment model achieves significantly worse rewards than
the long-term history alignment model (and the POMDP). These results suggest that treatments which may initially
appear attractive may result in poor patient outcomes at a later stage—unsurprising to many in HIV. Specifically,
resistance against a particular drug may lead to cross-resistance against another, leading to long-term dependencies in
therapy response.
The mixture-of-experts produces the best treatment policies. The mixture-of-experts approach outperforms the
other approaches across all evaluation schemes. While the POMDP performs worse than the long-term alignment kernel
in general, the fact that the mixture of experts approach outperforms both the POMDP and alignment kernel suggests
that these models are making mistakes in different places—and thus we can do better by choosing between the two. A
post-hoc investigation reveals that the mixture-of-experts chooses the POMDP model approximately 26% of the time in
comparison to the alignment kernel.
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The mixture-of-experts chooses experts based on clustering characteristics. We follow up on our clustering
hypothesis: when is the long-term history alignment method being chosen, and when is the POMDP being chosen?
Specifically, we consider role that a patient’s history and the lower quantile of their distance to other patients plays
here. Figure 2 (a) and (b) provide box plot illustrations of the values of the latter features in relation to the choice of
model selected by the mixture-of-experts. As the lower quantile of the distance between a patient and their neighbours
increases, the POMDP is more likely to become the model of choice. Moreover, the length of a patient’s therapy history
seems to play a defining role in the choice of expert. The mixture-of-experts selects the POMDP for patients with longer
history lengths and the alignment kernel for the others. One possible explanation for this would be that as a patient’s
treatment history increases in length, they become more unique and hence have smaller similarity values relative to
other patients in the kernel. In these instances the POMDP is the model of choice, possibly because of the fact that it is
able to incorporate this rich history into its belief state, while the alignment kernel cannot capture the same level of
information.
Discussion
In this paper, we demonstrated how kernel methods and model-based RL can be combined for HIV therapy selection
using a mixture-of-experts approach. The mixture-of-experts enabled us to account for heterogeneity in patient data,
that typically makes it difficult for a single model to provide reasonable therapy predictions for individuals. Kernel
methods attempt to group patients on the basis of similarity, and use this as a means of identifying optimal therapies,
while RL models treat patients as individuals and use past experience to reason about suitable therapies and outcomes.
By combining these approaches, we were able to take advantage of the strengths of each method in different situations.
Specifically, we showed that the kernel approach is optimal for patients with short treatment histories; these are
likely patients that are at early stages of infection, or those that are treatment-inexperienced. On the other hand, the
model-based method proved more suited to patients with long treatment histories and rare therapy combinations. These
are patients that have been heavily pre-treated. We attribute this difference directly to the way in which each model
uses a patient’s history: the POMDP incorporates knowledge about a patient’s history implicitly through its beliefs
and actions, each influenced by past observations, treatments and mutations, while the history alignment method only
uses patient’s treatment history from the kernel, and does not account for observations that occur further back in time.
Overall, the mixture-of-experts approach outperformed each method on its own as a result of its adaptability in various
patient situations.
There are many opportunities for future research. An interesting direction would be to incorporate the kernel-based
predictions directly into the reinforcement-learning models. Another potential aspect of interest would be to use such a
model to rank existing clinical policies for different scenarios.
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